Ocrevus (Ocrelizumab) Denied: Appealing MS Coverage Denials for RRMS and PPMS

Ocrevus (ocrelizumab) is an anti-CD20 monoclonal antibody FDA-approved for relapsing forms of multiple sclerosis (RRMS, CIS, SPMS with active disease) and primary progressive multiple sclerosis (PPMS). It is the first and only FDA-approved therapy for PPMS and represents a highly effective treatment for relapsing MS. Given its IV infusion administration, specialty tier pricing, and complex clinical criteria, Ocrevus denials are common — but also frequently overturned on appeal.

Why Ocrevus Gets Denied

MS type mismatch. The FDA approved Ocrevus for two distinct patient populations: relapsing forms of MS (including RRMS, clinically isolated syndrome, and secondary progressive MS with relapses) and primary progressive MS. Denials sometimes occur when the ICD-10 code submitted doesn't match the approved indication, or when the treating neurologist's notes describe the disease course ambiguously. The appeal must clearly state the MS type using established clinical criteria.

Step therapy after first-line DMTs. For relapsing MS, many insurers require documented failure of at least one first-line or moderate-efficacy disease-modifying therapy (DMT) — such as an interferon beta product (Avonex, Rebif, Betaseron, Plegridy), glatiramer acetate (Copaxone), or dimethyl fumarate (Tecfidera/Vumerity) — before approving high-efficacy therapies like Ocrevus. This requirement is particularly contested in neurology, where the "treat to target" and early high-efficacy approaches are increasingly supported by clinical evidence.

JC virus testing issues. Unlike Tysabri, Ocrevus is not formally linked to PML (progressive multifocal leukoencephalopathy) in a way that requires JC antibody testing under a REMS program. However, some insurers and some neurologists order JC serology as part of MS management. Denials related to JC testing are unusual for Ocrevus but can occur in plans that apply Tysabri protocols to all CD20 therapies.

PPMS documentation. PPMS is defined by progressive neurological deterioration from onset without relapses. Documentation must include confirmation of progressive disability accumulation over at least one year (determined retrospectively or prospectively), MRI brain/spine findings, and exclusion of relapsing disease. If the clinical record doesn't clearly establish the PPMS diagnosis, insurers deny.

Prior infusion reactions. If a patient had an infusion reaction during a prior Ocrevus infusion and the insurer uses this to deny re-authorization, the appeal should document that infusion-related reactions are manageable and do not constitute a contraindication to continued therapy when appropriate premedication protocols are followed.

Building the Step Therapy Bypass Argument for Relapsing MS

The most important argument for bypassing step therapy in MS appeals is the "early high-efficacy" treatment paradigm. Growing clinical evidence shows that:

1. Highly active relapsing MS (high lesion burden on MRI, multiple relapses per year, incomplete recovery from relapses) responds better to early high-efficacy therapy than to sequential step therapy
2. Delaying high-efficacy therapy while stepping through less effective agents results in irreversible axonal damage and disability accumulation
3. Multiple published studies and neurological society guidelines support initiating high-efficacy therapies earlier in the disease course for appropriate patients

Your neurologist's letter should document:

• Relapse frequency (number of relapses in the past 2 years)
• MRI activity (T2 lesion count, gadolinium-enhancing lesions)
• EDSS (Expanded Disability Status Scale) score
• Disability progression rate
• Evidence of highly active disease that clinically justifies bypassing step therapy

The PPMS Appeal

For PPMS patients, Ocrevus is the only approved therapy, which makes the appeal straightforward in concept — but requires meticulous documentation in practice. Include:

• Neurologist confirmation of PPMS diagnosis with criteria (one year of progressive disability accumulation plus two of: ≥1 T2 brain lesion in MS-characteristic location, ≥2 T2 spinal cord lesions, positive CSF for oligoclonal bands)
• EDSS at baseline and at time of prescription
• Absence of relapses to distinguish from SPMS

If the insurer denies PPMS coverage arguing lack of proven benefit (a dated argument given the ORATORIO trial results), the appeal should cite ORATORIO trial data showing significant reduction in disability progression compared to placebo.

Fight Back With ClaimBack

Ocrevus denials — particularly for PPMS — are among the most medically urgent specialty medication appeals. ClaimBack helps you build a neurology-specific appeal that addresses both the clinical criteria and the medical necessity arguments that matter most.

Start your Ocrevus appeal at ClaimBack

Related Reading

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• Internal vs. External Insurance Appeal: What's the Difference?